Developer docs
API playgroundTry for free, no card

Search company profiles

BAROnova

Full company profile

uuid0003dcz

Namestring
BAROnova
Websiteurl
baronova.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

BAROnova is a clinical-stage medical-device company founded in 2006 and headquartered in Goleta, California. The company's mission, as described in its firmographic profile, is to develop non-surgical, non-pharmacologic devices designed to induce weight loss, positioning it in the obesity-treatment market with a therapeutic modality that sits adjacent to bariatric surgery and weight-loss pharmacotherapy rather than competing head-on with either.

The company has been financed primarily through venture capital with strategic corporate participation. Public funding records show approximately $85.9 million raised across seven disclosed rounds between January 2006 and September 2016, comprising both equity Series-3 rounds and one venture-debt facility. The investor base spans dedicated healthcare VCs (Arboretum Ventures, Highland Capital Partners, ONSET Ventures, Sante Ventures, Lumira Ventures, Longitude Capital, Delos Capital) and two notable strategic corporate investors - Allergan (lead in the 2008 round) and Boston Scientific (lead in the 2013 round). The 2015 Series 3 at $36.5 million was the largest single equity raise in the company's history.

BAROnova operates with a headcount of 11-50 employees, consistent with a lean clinical-stage medical-device company in the R&D and regulatory pathway phase. Its publicly listed management includes a CEO & President (Hugh Narciso), a President & CEO (David Thrower), and an SVP of Clinical Affairs & Regulatory Affairs (Lian Cunningham). The company's website (baronova.com) presents only a loader/verification page in the scraped data, typical of a private clinical-stage entity with limited public-facing communications. Pricing, reimbursement strategy, distribution channels, payer mix, customer segments, and revenue mechanics are not disclosed in the available input, consistent with a pre-commercial posture.

Short descriptiontext

BAROnova is a clinical-stage medical-device company founded in 2006 that develops non-surgical, non-pharmacologic devices designed to induce weight loss. The company is headquartered in Goleta, California.

Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSan Carlos, United States
HQ citystring
San Carlos
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
weight loss devices, medical devices, obesity treatment, non-surgical devices, bariatric devices
Industry1 code
PRIMARYHLAKADAL
Obesity Medicine & Weight Management
NAICS code2 codes
  • Medical Equipment and Supplies Manufacturing3391
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Obesity Treatment Medical Devices
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

BAROnova is a clinical-stage medical device company developing non-surgical, non-pharmacologic devices designed to induce weight loss. The company focuses on creating proprietary gastrointestinal implant-based technologies intended for the treatment of obesity as an alternative to surgical and pharmaceutical interventions.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Non-surgical, non-pharmacologic weight loss device
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developer of the Allurion (formerly Elipse) swallowable, procedure-less gastric balloon for weight loss; directly comparable as a non-surgical, non-pharmacologic weight-loss device targeting the same patient and physician segments.

TypeDirect peer
Description

Markets the Orbera intragastric balloon system for endoscopic weight-loss intervention; directly comparable as an approved, commercially available weight-loss device competing for the same bariatric and gastroenterology channels.

TypeDirect peer
Description

Maker of the Spatz3 adjustable intragastric balloon, an endoscopic weight-loss device; directly comparable mechanism and target market as a non-pharmacologic obesity device.

TypeDirect peer
Description

Developed the Obalon gas-filled intragastric balloon system for non-surgical weight loss; directly comparable as a swallowable/non-surgical weight-loss device targeting similar patient populations.

TypeDirect peer
Description

Developed Plenity, an oral hydrogel capsule for weight management; comparable as a non-surgical, non-procedural weight-loss intervention competing for the same physician-prescribed obesity category.

6ReShape Medical
TypeDirect peer
Description

Developed the ReShape intragastric balloon and later the vBloc neurometabolic system (via EnteroMedics acquisition); directly comparable as a non-pharmacologic weight-loss device company.

TypeDirect peer
Description

Developer of vBloc, an implantable neurometabolic device for obesity treatment; comparable as a medical-device approach to obesity positioned between drugs and surgery.

8AspireAssist (Aspire Bariatrics)
TypeDirect peer
Description

Developer of the AspireAssist percutaneous gastrostomy aspiration device for weight loss; comparable as an interventional, non-pharmacologic obesity device targeting similar patient demographics.

TypeBroad incumbent
Description

Large-cap medical-device incumbent and prior investor in BAROnova; overlapping interests in endoscopic and bariatric interventions, providing a strategic exit reference point and a broad incumbent with adjacent weight-loss capabilities.

TypeBroad incumbent
Description

Earlier investor in BAROnova with historical bariatric and obesity franchises (e.g., Lap-Band via Apollo Endosurgery); relevant incumbent for strategic benchmarking and as an acquirer reference in the obesity-device category.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BAROnova

Obesity Treatment Medical Devicesbaronova.com

BAROnova is a clinical-stage medical-device company founded in 2006 that develops non-surgical, non-pharmacologic devices designed to induce weight loss. The company is headquartered in Goleta, California.

What BAROnova does

BAROnova is a clinical-stage medical-device company founded in 2006 and headquartered in Goleta, California. The company's mission, as described in its firmographic profile, is to develop non-surgical, non-pharmacologic devices designed to induce weight loss, positioning it in the obesity-treatment market with a therapeutic modality that sits adjacent to bariatric surgery and weight-loss pharmacotherapy rather than competing head-on with either.

The company has been financed primarily through venture capital with strategic corporate participation. Public funding records show approximately $85.9 million raised across seven disclosed rounds between January 2006 and September 2016, comprising both equity Series-3 rounds and one venture-debt facility. The investor base spans dedicated healthcare VCs (Arboretum Ventures, Highland Capital Partners, ONSET Ventures, Sante Ventures, Lumira Ventures, Longitude Capital, Delos Capital) and two notable strategic corporate investors - Allergan (lead in the 2008 round) and Boston Scientific (lead in the 2013 round). The 2015 Series 3 at $36.5 million was the largest single equity raise in the company's history.

BAROnova operates with a headcount of 11-50 employees, consistent with a lean clinical-stage medical-device company in the R&D and regulatory pathway phase. Its publicly listed management includes a CEO & President (Hugh Narciso), a President & CEO (David Thrower), and an SVP of Clinical Affairs & Regulatory Affairs (Lian Cunningham). The company's website (baronova.com) presents only a loader/verification page in the scraped data, typical of a private clinical-stage entity with limited public-facing communications. Pricing, reimbursement strategy, distribution channels, payer mix, customer segments, and revenue mechanics are not disclosed in the available input, consistent with a pre-commercial posture.

BAROnova firmographics

Firmographics
Name
BAROnova
Website
https://baronova.com
Company type
Private
Founded year
2006
Headcount range
51–100 employees
Short description
BAROnova is a clinical-stage medical-device company founded in 2006 that develops non-surgical, non-pharmacologic devices designed to induce weight loss. The company is headquartered in Goleta, California.
Ownership category
akta.pro rank

BAROnova industry classification

Industry
Product category
Obesity Treatment Medical Devices
NAICS
Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAKADAL
Obesity Medicine & Weight Management

Keywords

  • Weight loss devices
  • Medical devices
  • Obesity treatment
  • Non-surgical devices
  • Bariatric devices

Where BAROnova is headquartered

Location

Headquarters

HQ city
San Carlos
HQ country
United States
HQ region
North America

Markets served

BAROnova business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

BAROnova product offering

Product offering

Core offering

BAROnova is a clinical-stage medical device company developing non-surgical, non-pharmacologic devices designed to induce weight loss. The company focuses on creating proprietary gastrointestinal implant-based technologies intended for the treatment of obesity as an alternative to surgical and pharmaceutical interventions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Non-surgical, non-pharmacologic weight loss device

Companies that use BAROnova

Customer profile

Ideal customer profiles1 record

BAROnova technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

BAROnova partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights4 records

BAROnova competitors and assessment

Company assessment

Direct peers

  • Allurion Technologies: Developer of the Allurion (formerly Elipse) swallowable, procedure-less gastric balloon for weight loss; directly comparable as a non-surgical, non-pharmacologic weight-loss device targeting the same patient and physician segments.
  • Apollo Endosurgery: Markets the Orbera intragastric balloon system for endoscopic weight-loss intervention; directly comparable as an approved, commercially available weight-loss device competing for the same bariatric and gastroenterology channels.
  • Spatz FGIA: Maker of the Spatz3 adjustable intragastric balloon, an endoscopic weight-loss device; directly comparable mechanism and target market as a non-pharmacologic obesity device.
  • Obalon Therapeutics: Developed the Obalon gas-filled intragastric balloon system for non-surgical weight loss; directly comparable as a swallowable/non-surgical weight-loss device targeting similar patient populations.
  • Gelesis: Developed Plenity, an oral hydrogel capsule for weight management; comparable as a non-surgical, non-procedural weight-loss intervention competing for the same physician-prescribed obesity category.
  • ReShape Medical: Developed the ReShape intragastric balloon and later the vBloc neurometabolic system (via EnteroMedics acquisition); directly comparable as a non-pharmacologic weight-loss device company.
  • EnteroMedics: Developer of vBloc, an implantable neurometabolic device for obesity treatment; comparable as a medical-device approach to obesity positioned between drugs and surgery.
  • AspireAssist (Aspire Bariatrics): Developer of the AspireAssist percutaneous gastrostomy aspiration device for weight loss; comparable as an interventional, non-pharmacologic obesity device targeting similar patient demographics.

Broad incumbents

  • Boston Scientific: Large-cap medical-device incumbent and prior investor in BAROnova; overlapping interests in endoscopic and bariatric interventions, providing a strategic exit reference point and a broad incumbent with adjacent weight-loss capabilities.
  • Allergan (now AbbVie): Earlier investor in BAROnova with historical bariatric and obesity franchises (e.g., Lap-Band via Apollo Endosurgery); relevant incumbent for strategic benchmarking and as an acquirer reference in the obesity-device category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

BAROnova social profiles

Digital presence

BAROnova financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BAROnova leadership team

Management profile

Number of profiles

Profiles3 records

BAROnova funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BAROnova M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BAROnova

What does BAROnova do?

BAROnova is a clinical-stage medical device company developing non-surgical, non-pharmacologic devices designed to induce weight loss. The company focuses on creating proprietary gastrointestinal implant-based technologies intended for the treatment of obesity as an alternative to surgical and pharmaceutical interventions.

When was BAROnova founded?

BAROnova was founded in 2006. It employs 51 to 100 people.

Where is BAROnova based?

BAROnova is headquartered in San Carlos, United States, in the North America region.

Who are BAROnova's main competitors?

Direct peers on record are Allurion Technologies, Apollo Endosurgery, Spatz FGIA, Obalon Therapeutics, Gelesis, ReShape Medical, EnteroMedics and AspireAssist (Aspire Bariatrics). Broad incumbents are Boston Scientific and Allergan (now AbbVie).

Does BAROnova have an API?

No public API is recorded for BAROnova.

What industry is BAROnova in?

BAROnova's product category is Obesity Treatment Medical Devices. Its primary akta.pro industry code is HLAKADAL, Obesity Medicine & Weight Management. Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Regulations.govRegulations.govThe U.S. Food and Drug Administration (FDA) has finalized the classification of the anchored esophageal sheath into Class II, establishing special controls to ensure its safety and effectiveness. This regulatory action was taken in response to a request from BAROnova, Inc., allowing the device to be marketed with reduced regulatory burdens while maintaining patient safety standards.PR NewswireBAROnova Announces FDA Approval of the TransPyloric Shuttle® (TPS®) DeviceBAROnova, Inc. announced FDA approval of its TransPyloric Shuttle (TPS) Device, a non-surgical weight loss solution for adults with obesity (BMI 30-40 kg/m2), approved for up to 12 months of treatment. The pivotal trial showed patients treated with TPS lost an average of 9.5% body weight compared to 2.8% for the sham-control group, with approximately 67% of TPS-treated patients achieving clinically meaningful weight loss of 5% or more. The device features a mechanical design approximately 85-90% smaller than fluid-filled intragastric balloons and offers twice the treatment duration of currently approved U.S. intragastric balloons.PR NewswireBAROnova Announces Submission of Premarket Approval (PMA) Application to the U.S. FDA for the TransPyloric Shuttle® (TPS®) Device Intended for the Treatment of ObesityBAROnova, Inc. announced the submission of a Pre-Market Approval (PMA) application to the U.S. FDA for its TransPyloric Shuttle (TPS) device, intended for the non-surgical treatment of obesity. The submission is based on positive results from the ENDObesity II pivotal trial, which enrolled 302 patients and successfully met its primary endpoints regarding weight loss. If approved, the TPS would be the first intragastric implant in the United States with a 12-month duration of action.PR NewswireBAROnova Announces Completion of ENDObesity® II Pivotal Clinical Trial EnrollmentBAROnova announced completion of enrollment in its ENDObesity II pivotal clinical trial for the TransPyloric Shuttle (TPS) device, having enrolled 270 patients at 9 sites in the United States in December 2016. The trial results will support an FDA application for device approval, and prior feasibility data demonstrated an average 14.7% total body weight loss after six months. If approved, the TransPyloric Shuttle would be the first intra-gastric device with a twelve-month stomach dwell time, potentially offering a longer-treatment-duration weight-loss option for the over 100 million medically obese individuals in the US.PR NewswireBAROnova Announces Appointment of David S. Thrower as President and Chief Executive OfficerBAROnova, Inc., a clinical-stage medical technology company developing devices for obesity treatment, announced the appointment of David S. Thrower as President and Chief Executive Officer, effective immediately. Thrower, who brings over two decades of medical device executive experience, joins from Asante Solutions where he led the commercial launch of a novel insulin pump and previously led InSound Medical, which was acquired by Sonova Holdings AG. The appointment comes as BAROnova advances its TransPyloric Shuttle device through a pivotal clinical trial intended to support FDA approval for the weight-loss device.VC News DailyBAROnova Secures $36.5MBAROnova, a clinical-stage medical technology company based in Goleta, California, has closed a $36.5 million Series D financing round led by Delos Capital and co-led by Longitude Capital, with participation from existing investors Lumira Capital Partners, ONSET Ventures, and Sante Ventures. The company will use the proceeds to fund the U.S. pivotal clinical study of its TransPyloric Shuttle (TPS) weight-loss device, which recently received unconditional FDA approval to begin the ENDObesity II Study. The first subject enrollment is expected before the end of 2015.PR NewswireBAROnova Announces Enrollment of First Patients in the ENDObesity II Pivotal Clinical TrialBAROnova announced enrollment of the first four patients in its ENDObesity II pivotal trial testing the TransPyloric Shuttle for obesity. The 12-month multicenter study is projected to enroll 270 patients at up to 12 U.S. sites, with results expected to support an FDA application for TPS approval.FinSMEsBAROnova Raises $27.3M in Series C FinancingBAROnova raised $27.3M in Series C financing led by Sante Ventures and Boston Scientific. The company will use the funds for a pivotal study of its TransPyloric Shuttle device to obtain US and European regulatory approvals.VC News DailyBAROnova Secures $27.3M Series CBAROnova announced the closing of its $27.3 million Series C financing round, led by Sante Ventures and Boston Scientific Corporation. The company intends to use the proceeds to fund a pivotal study for its TransPyloric Shuttle device to secure regulatory approvals in the US and Europe.